前列腺影像报告和数据系统5分病变患者适合主动监测吗?一项欧洲多中心研究
该多中心回顾性研究分析了16个中心126例初始磁共振显示至少一个PI-RADS 5分病变并接受主动监测的患者。中位随访36个月后,5年生化复发无生存率为88%,无转移进展,55例停止主动监测,5年停止主动监测无生存率为41%。作者认为在严格监测下,主动监测是PI-RADS 5分病变且有利风险前列腺癌患者的安全选择。
要点
- PI-RADS 5分病变患者主动监测5年生化复发无生存率为88%(95%CI 79-99%)。
- 中位随访36个月期间无转移进展,55例(共126例)停止主动监测。
- 基线前列腺特异性抗原密度和阳性活检针数百分比与活检分级再分类、停止主动监测和生化复发相关。
核心结论
- 在严格监测下,主动监测是PI-RADS 5分病变且有利风险前列腺癌患者的安全管理选择。
研究设计与样本
- 回顾性多中心研究,纳入法国、意大利、瑞士和比利时16个中心的126例患者,初始磁共振显示至少一个PI-RADS 5分病变并接受主动监测。
主要发现
- 中位随访36个月(95%CI 23-55)后,5例发生生化复发,中位时间未达到,5年生化复发无生存率为88%(95%CI 79-99%)。
- 未报告转移进展。
- 17例发生活检分级再分类(中位时间未达到),55例停止主动监测,中位停止时间为55个月(95%CI 46个月-不适用),5年停止主动监测无生存率为41%(95%CI 30.8-54.6%)。
- 多变量Cox回归分析显示,基线前列腺特异性抗原密度和阳性活检针数百分比与活检分级再分类、停止主动监测和生化复发相关。
临床怎么用
- 作者认为,在严格监测下,主动监测是PI-RADS 5分病变且有利风险前列腺癌患者的安全管理选择。
局限性
- 局限性主要在于本研究的回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions are at a high risk of clinically significant prostate cancer (PCa), extracapsular extension, and biochemical recurrence (BCR) after local treatment. Managing these patients with active surveillance (AS) can be particularly challenging when targeted biopsies indicate favorable-risk tumors. This study aims to evaluate the outcomes of patients with PI-RADS 5 lesions managed with AS. METHODS: We analyzed data from 126 patients treated at 16 centers in France, Italy, Switzerland, and Belgium, whose initial magnetic resonance imaging revealed at least one PI-RADS 5 lesion and who subsequently underwent AS. The primary endpoint was BCR-free survival. The secondary endpoints included metastasis-free survival, time to biopsy grade reclassification, and time to AS discontinuation, along with their predictors. KEY FINDINGS AND LIMITATIONS: After a median follow-up of 36 mo after confirmatory biopsies (95% confidence interval [CI] 23-55), BCR was observed in five patients, with the median time not reached. The 5-yr BCR-free survival rate was 88% (95% CI 79-99%). No metastatic progression was reported. Seventeen patients experienced biopsy grade reclassification (median time not reached), and 55 patients discontinued AS. The median time to AS discontinuation was 55 mo (95% CI 46 mo-not applicable). The 5-yr AS discontinuation-free survival rate was 41% (95% CI 30.8-54.6%). On a multivariate Cox regression analysis, baseline prostate-specific antigen density and the percentage of positive biopsy cores were associated with biopsy grade reclassification, AS discontinuation, and BCR. CONCLUSIONS AND CLINICAL IMPLICATIONS: With strict monitoring, AS is a safe management option for patients with PI-RADS 5 lesions and favorable-risk PCa. Limitations are mainly inherent to the retrospective design of this study.
引用
- Peyrottes A, Baboudjian M, Diamand R, et al. Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study. Eur Urol Oncol. 2025. PMID: 39965998. doi:10.1016/j.euo.2025.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。